Ropes & Gray represented Xeris Biopharma in a research collaboration and option agreement with Horizon Therapeutics.
Under the agreement announced on November 23, Xeris will use its proprietary formulation technology platform, XeriJect, to develop an ultra-concentrated ready-to-use, subcutaneous injection of Horizon’s teprotumumab, and Horizon will have an option to take a commercial license under the Xeris technology to exploit such re-formulated product.
Teprotumumab is the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of Thyroid Eye Disease – a serious, progressive and potentially vision-threatening rare autoimmune disease. Xeris will receive an upfront payment, and may be entitled to receive development milestones, regulatory milestones, and sales-based milestones, as well as royalties based on future sales if the commercial license option is exercised. Financial terms of the agreement were not disclosed.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and included tax partner Scott Pinarchick and strategic transactions associates Joe Muller and Adwoa Hinson.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
